USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase

Cell Death and Differentiation

Volumn 20, Issue 5, 2013, Pages 721-731

  Giovinazzi, S ^a   Morozov, V M ^a   Summers, M K ^b   Reinhold, W C ^c   Ishov, A M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Aurora A; CHFR; Daxx; mitosis; taxanes; USP7

Indexed keywords

AURORA A KINASE; CHECKPOINT WITH FORKHEAD AND RING FINGER PROTEIN; CYCLIN B; DAXX PROTEIN; PROTEIN P53; PROTEINASE; RING FINGER PROTEIN; TAXANE DERIVATIVE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN SPECIFIC PROCESSING PROTEASE 7; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; COLONY FORMATION; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BENZAZEPINES; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN B; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MITOSIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE;

EID: 84877578784     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.169     Document Type: Article

References (60)

1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10(Suppl 3): 20-29.
2. Higa GM. The microtubule as a breast cancer target. Breast Cancer 2010; 18: 103-119.
3. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3: 193-203.
4. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005; 4: 1495-1504.
5. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-651.
6. Matson DR, Stukenberg PT. Spindle poisons and cell fate: a tale of two pathways. Mol Interv 2010; 11: 141-150.
7. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-393.
8. Mantel C, Guo Y, Lee MR, Han MK, Rhorabough S, Kim KS et al. Cells enter a unique intermediate 4 N stage, not 4 N-G1, after aborted mitosis. Cell Cycle 2008; 7: 484-492.
9. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006; 16: 1194-1200.
10. Bonneterre J, Spielman M, Guastalla JP, Marty M, Viens P, Chollet P et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35: 1431-1439.
11. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005; 5: 65-71.
12. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 2008; 35(Suppl 2): S1-S14; quiz S39.
13. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004; 3: 661-669.
14. Brito DA, Yang Z, Rieder CL. Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J Cell Biol 2008; 182: 623-629.
15. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5: 1001-1007.
16. Xia G, Luo X, Habu T, Rizo J, Matsumoto T, Yu H. Conformation-specific binding of p31(comet) antagonizes the function of Mad2 in the spindle checkpoint. EMBO J 2004; 23: 3133-3143.
17. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51-62.
18. Staff S, Isola J, Jumppanen M, Tanner M. Aurora-A gene is frequently amplified in basallike breast cancer. Oncol Rep 2010; 23: 307-312.
19. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006; 12: 6869-6875.
20. Lindsay CR, Scholz A, Morozov VM, Ishov AM. Daxx shortens mitotic arrest caused by paclitaxel. Cell Cycle 2007; 6: 1200-1204.
21. Giovinazzi S, Lindsay CR, Morozov VM, Escobar-Cabrera E, Summers MK, Han HS et al. Regulation of mitosis and taxane response by Daxx and Rassf1. Oncogene 2012; 31: 13-26.
22. Lindsay CR, Morozov VM, Ishov AM. PML NBs (ND10) and Daxx: from nuclear structure to protein function. Front Biosci 2008; 13: 7132-7142.
23. Lindsay CR, Giovinazzi S, Ishov AM. Daxx is a predominately nuclear protein that does not translocate to the cytoplasm in response to cell stress. Cell Cycle 2009; 8: 1544-1551.
24. Salomoni P, Khelifi AF. Daxx: death or survival protein? Trends Cell Biol 2006; 16: 97-104.
25. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333: 425.
26. Morozov VM, Massoll NA, Vladimirova OV, Maul GG, Ishov AM. Regulation of c-met expression by transcription repressor Daxx. Oncogene 2008; 27: 2177-2186.
27. Boutell C, Canning M, Orr A, Everett RD. Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J Virol 2005; 79: 12342-12354.
28. Oh YM, Yoo SJ, Seol JH. Deubiquitination of Chfr, a checkpoint protein, by USP7/HAUSP regulates its stability and activity. Biochem Biophys Res Commun 2007; 357: 615-619.
29. Nakatani Y, Ogryzko V. Immunoaffinity purification of mammalian protein complexes. Methods Enzymol 2003; 370: 430-444.
30. Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem Biophys 2011; 60: 61-68.
31. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002; 416: 648-653.
32. Cummins JM, Vogelstein B. HAUSP is required for p53 destabilization. Cell Cycle 2004; 3: 689-692.
33. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY et al. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 2006; 8: 855-862.
34. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009; 106: 3964-3969.
35. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD et al. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003; 24: 47-51.
36. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 2003; 100: 7818-7823.
37. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ et al. Chfr is required for tumor suppression and Aurora-A regulation. Nat Genet 2005; 37: 401-406.
38. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007; 120(Part 17): 2987-2996.
39. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114: 585-598.
40. Qin L, Tong T, Song Y, Xue L, Fan F, Zhan Q. Aurora-A interacts with cyclin B1 and enhances its stability. Cancer Lett 2009; 275: 77-85.
41. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004; 14: 29-36.
42. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010; 9: 1080-1091.
43. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metast Rev 2003; 22: 451-464.
44. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N et al. MLN8054, a smallmolecule inhibitor of Aurora-A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007; 27: 4513-4525.
45. Sun C, Chan F, Briassouli P, Linardopoulos S. Aurora kinase inhibition downregulates NFkappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun 2007; 352: 220-225.
46. Kon N, Kobayashi Y, Li M, Brooks CL, Ludwig T, Gu W. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 2009; 29: 1270-1279.
47. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
48. Kon N, Zhong J, Kobayashi Y, Li M, Szabolcs M, Ludwig T et al. Roles of HAUSP-mediated p53 regulation in central nervous system development. Cell Death Differ 2011; 18: 1366-1375.
49. Faesen AC, Dirac AM, Shanmugham A, Ovaa H, Perrakis A, Sixma TK. Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol Cell 2011; 44: 147-159.
50. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53/cells. EMBO J 2002; 21: 483-492.
51. Tang J, Qu L, Pang M, Yang X. Daxx is reciprocally regulated by Mdm2 and Hausp. Biochem Biophys Res Commun 2010; 393: 542-545.
52. Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y et al. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol 2007; 31: 713-720.
53. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000; 406: 430-435.
54. Wysong DR, Chakravarty A, Hoar K, Ecsedy JA. The inhibition of Aurora-A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 2009; 8: 876-888.
55. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65: 2899-2905.
56. Rong R, Jiang LY, Sheikh MS, Huang Y. Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene 2007; 26: 7700-7708.
57. Liu L, Baier K, Dammann R, Pfeifer GP. The tumor suppressor RASSF1A does not interact with Cdc20, an activator of the anaphase-promoting complex. Cell Cycle 2007; 6: 1663-1665.
58. Ishov AM, Vladimirova OV, Maul GG. Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX. J Cell Sci 2004; 117(Part 17): 3807-3820.
59. Reinhold WC, Erliandri I, Liu H, Zoppoli G, Pommier Y, Larionov V. Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability. PLoS One 2011; 6: e25991.
60. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990; 82: 1113-1118.